Atlas Trials

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Clinical trial NCT05562934 · COMPLETED

Trial details

NCT number
NCT05562934
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Resistant Hypertension
Start date
2022-11-08
Primary completion
2024-07-02
Enrollment
189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.